BSX vs ABT
BSX and ABT side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BSXBOSTON SCIENTIFIC CORPORATION | ABTABBOTT LABORATORIES |
|---|---|---|
| Market cap | $63.59B | $177.72B |
| P/E (TTM) | 17.8 | 28.6 |
| P/B | 2.55 | 3.41 |
| P/S | 3.2x | 4.0x |
| Dividend yield | — | 2.32% |
| Revenue | $21.00B(TTM) | $45.13B(TTM) |
| Revenue growth (YoY) | 19.9% | 5.7% |
| Net income | $3.67B(TTM) | $6.28B(TTM) |
| Earnings growth (YoY) | 56.7% | -51.3% |
| EPS, diluted | $2.47(TTM) | $3.57(TTM) |
| EBIT margin | 18.0% | 18.2% |
| ROE | 11.6% | 12.5% |
| ROIC | 10.0% | 8.3% |
| Piotroski F | 8/9 | — |
| 1y total return | -56.1% | -20.5% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: BSX vs ABT
| Metric | BSX | ABT |
|---|---|---|
| End value | $19.9K | $32.6K |
| Total return | +99.0% | +226.1% |
| CAGR | +6.9% | +12.1% |
| Volatility | 27.4% | 23.9% |
| Sharpe | 0.23 | 0.43 |
| Sortino | 0.31 | 0.61 |
| Max drawdown | -60.6% | -39.6% |
Based on 2600 common trading days, 2016-05-12 → 2026-09-15 · risk-free 4.11% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)